# EDGAR Filing Document

**Accession Number:** 0001872789
**File Stem:** 0000947871-25-001028
**Filing Date:** 2025-11
**Character Count:** 11982
**Document Hash:** d427df353997e64561561b10458a2fc2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000947871-25-001028.hdr.sgml**: 20251117

**ACCESSION NUMBER**: 0000947871-25-001028

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251117

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251117

**DATE AS OF CHANGE**: 20251117

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Embecta Corp.
- **CENTRAL INDEX KEY:** 0001872789
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 871583942
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41186
- **FILM NUMBER:** 251491804

**BUSINESS ADDRESS:**
- **STREET 1:** 1209 ORANGE STREET
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801
- **BUSINESS PHONE:** 8624010000

**MAIL ADDRESS:**
- **STREET 1:** 1209 ORANGE STREET
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Berra Newco, Inc.
- **DATE OF NAME CHANGE:** 20210714

?xml version='1.0' encoding='ASCII'?

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 17, 2025**

**EMBECTA CORP.**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Delaware<br> (State or Other Jurisdiction of Incorporation)** | &nbsp;&nbsp;**Delaware<br> (State or Other Jurisdiction of Incorporation)** |
| &nbsp;&nbsp;**001-41186<br> (Commission File Number)** | &nbsp;&nbsp;**87-1583942<br> (IRS Employer <br> Identification No.)** |
| &nbsp;&nbsp;**300 Kimball Drive, Suite 300, Parsippany, New Jersey<br> (Address of principal executive offices)** | &nbsp;&nbsp;**07054<br> (Zip Code)** |
| &nbsp;&nbsp;**Registrant's telephone number, including area code: (862) 401-0000** | &nbsp;&nbsp;**Registrant's telephone number, including area code: (862) 401-0000** |
| &nbsp;&nbsp;**N/A<br> (Former name or former address, if changed since last report)** | &nbsp;&nbsp;**N/A<br> (Former name or former address, if changed since last report)** |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| | |
|:---|:---|
| &nbsp;&nbsp; **Title of each class** | &nbsp;&nbsp; **Name of each exchange<br> on which registered** |
| &nbsp;&nbsp;**Common Stock, par value $0.01 per share** &nbsp;&nbsp;**EMBC** | &nbsp;&nbsp;**The Nasdaq Stock Market LLC (Nasdaq Global Select Market)** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

 ****

***Departure of Directors***

 

On November 17, 2025, David A. Albritton, a member of the board of directors (the "Board") of Embecta Corp. (the "Company"), the Corporate Governance and Nominating Committee of the Board and the Technology, Quality and Regulatory Committee of the Board, notified the Company of his intention to resign due to personal reasons, effective immediately. Mr. Albritton has served as a director of the Company since April 2022. Mr. Albritton's resignation was not the result of any disagreement with the Company or any matter relating to its operations, policies or practices.

On November 17, 2025, LTG (Ret.) David F. Melcher, a member of the Board and the Non-Executive Chairman of the Board, notified the Company of his decision not to stand for re-election at the Company's 2026 annual meeting of stockholders. LTG Melcher has served as a director of the Company since April 2022. LTG Melcher's decision not to stand for reelection was not the result of any disagreement with the Company or any matter relating to its operations, policies or practices.

In connection with the resignation of Mr. Albritton, the size of the Board was decreased from nine to eight members.

***Appointment of Chairman of the Board and Lead Independent Director***

The Company's independent directors expect to appoint Devdatt (Dev) Kurdikar as the Chairman of the Board and Dr. Claire Pomeroy as the Board's Lead Independent Director, each effective upon LTG Melcher's departure from the Board at the Company's 2026 annual meeting of stockholders. Dr. Pomeroy and Mr. Kurdikar have served on the Board since April 2022. Dr. Pomeroy currently serves as Chair of the Corporate Governance and Nominating Committee and as a member of the Technology, Quality and Regulatory Committee, and Mr. Kurdikar currently serves as the President and Chief Executive Officer of the Company.

**Item 9.01 Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| (d) Exhibits | (d) Exhibits |
| Exhibit | Description |
| 99.1 | [Press Release dated November 17, 2025.](ss5610813_ex9901.htm) |
| 104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Date: November 17, 2025 | **EMBECTA CORP.** |

---

---

| | |
|:---|:---|
| By: | /s/ Jeff Mann |
|  | Jeff Mann |
|  | Senior Vice President, General Counsel & Product<br> Development, and Corporate Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**

![](image_01.jpg)

**embecta announces changes to Board of Directors**

PARSIPPANY, N.J., Nov. 17, 2025 -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that David J. Albritton, a member of the Board of Directors (the "Board") of embecta, has resigned from the Board due to personal reasons, effective immediately. In addition, LTG (Ret.) David F. Melcher, Non-Executive Chairman of the Board, has informed the company that he will not stand for re-election at embecta's 2026 annual stockholder meeting and will retire from the Board at that time due to several commitments outside of his service to the Company. Both have been Directors since the Board's inception in 2022.

"On behalf of the entire Board of Directors and the global embecta team, I want to thank both of them for lending their experience, wisdom and guidance as we launched a new company in a dynamic environment," said Devdatt "Dev" Kurdikar, President and Chief Executive Officer. "Each has brought invaluable leadership experience that helped us successfully navigate the unique challenges of separating and standing up embecta. In particular, I wish to thank David Albritton for his contributions in shaping our corporate identity and communications efforts as we worked to establish embecta and provide an unflinching focus on care for people living with diabetes."

Mr. Kurdikar added, "I personally have benefited immensely from Dave Melcher's leadership and mentoring since his appointment as Chair of our Board. His counsel and support as we executed multiple complex initiatives in a challenging macroenvironment have been an integral part of our ability to execute all our stand-up programs. I am deeply grateful for Dave's service and contributions to our company."

"It has been a privilege to serve as Chairman of such a distinguished and collegial Board of Directors," said LTG Melcher. "As embecta transitions from its initial standup phase to one where we begin to seed growth, the company's strategic direction and priorities are clear. I'm confident that the ongoing stewardship of Dev and the rest of the Board will enable embecta to continue to prioritize the needs of our customers, employees and shareholders."

The Board expects to appoint Mr. Kurdikar as Chairman of the Board, and Dr. Claire Pomeroy, who has also served on the Board since its inception, as Lead Independent Director, each effective upon LTG Melcher's departure from the Board. The Corporate Governance and Nominating Committee will assess what expertise may be desired from future independent directors in view of the strategic direction of the company and accordingly recommend any potential replacements for the departing Directors.

**About embecta** 

embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit <u>embecta.com</u> or follow our social channels on <u>LinkedIn</u>, <u>Facebook</u>, and <u>Instagram</u>.

**Safe Harbor Statement Regarding Forward-Looking Statements**

This press release contains express or implied "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements concern our current expectations regarding strategic direction and priorities and expectations regarding our Board composition. These forward-looking statements are subject to various known and unknown risks, uncertainties and other factors, and you should not rely upon them except as statements of our present intentions and of our present expectations, which may or may not occur. When we use words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "pursue," "will," "goal" or similar expressions, we are making forward-looking statements. Although we believe that our forward-looking statements are based on reasonable assumptions, our expected results may not be achieved, and actual results may differ materially from our expectations. In addition, important factors that could cause actual results to differ from expectations include, among others, the risks described in our periodic reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors" in our most recent Annual Report on Form 10-K, as further updated by our Quarterly Reports on Form 10-Q we have filed or will file hereafter. Except as required by law, we undertake no obligation to update any forward-looking statements appearing in this release.

**Contacts:**

---

| | |
|:---|:---|
| Media | Investors |
| Christian Glazar | Pravesh Khandelwal |
| Sr. Director, Corporate Communications | VP, Head of Investor Relations |
| 908-821-6922 | 551-264-6547 |
| <u>Contact Media Relations</u> | <u>Contact IR</u> |

---

###